Cargando…
Drug-Induced Liver Injury From Sacubitril-Valsartan Versus a Single Dose of Acarbose
Numerous known medications can induce liver injury. Sacubitril-valsartan was approved by the Food and Drug Administration in 2015 for use in patients with chronic heart failure to reduce the rate of cardiovascular death and hospitalizations related to heart failure. There are yet to be any reported...
Autores principales: | Achuthanandan, Supraja, Dhaliwal, Amit, Patti, Ravikaran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386752/ https://www.ncbi.nlm.nih.gov/pubmed/35989811 http://dx.doi.org/10.7759/cureus.27005 |
Ejemplares similares
-
Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021) -
COVID-19 Resulting in Global Stress Cardiomyopathy in a Young Female
por: Achuthanandan, Supraja, et al.
Publicado: (2022) -
Efficacy of Sacubitril/Valsartan in the Setting of Acute Heart Failure: A Systematic Review
por: Mohyeldin, Moiud, et al.
Publicado: (2021) -
Sacubitril/Valsartan in Heart Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away?
por: Sakhamuri, Navya, et al.
Publicado: (2023) -
Devastating Worsening Renal Function Following the Initiation of Sacubitril/Valsartan: Falling Between Two Stools
por: Sairaku, Akinori, et al.
Publicado: (2023)